Literature DB >> 23451809

Evaluation of histological grade and histologically tumour-free margins as predictors of local recurrence in completely excised canine mast cell tumours.

L Donnelly1, C Mullin, J Balko, M Goldschmidt, E Krick, C Hume, D C Brown, K Sorenmo.   

Abstract

Completeness of mast cell tumour (MCT) excision is determined by assessment of histologically tumour-free margins (HTFM). The HTFM width necessary to prevent local recurrence (LR), recognized as histologic safety margin (HSM) in human oncology, has not been defined. We hypothesized that HTFM width would correlate with risk for LR and high-grade tumours would require wider HTFM than low-grade tumours. Records of dogs with completely excised MCTs were included. Signalment, two-tier tumour grade, tumour size, HTFM width, recurrence and therapy data was collected. High-grade (n = 39) tumours were more likely to recur than low-grade (n = 51) tumours (35.9% versus 3.9%), P < 0.0001, with no association between HTFM width and LR. Twenty-nine percent of low-grade tumours had HTFM less than 3 mm; none recurred. Narrow (≤3 mm) histologic margins are likely adequate to prevent LR of low-grade tumours. High-grade tumours have significant risk of LR regardless of HTFM width.
© 2013 University of Pennsylvania © 2013 Blackwell Publishing Ltd.

Entities:  

Keywords:  canine; grade; histologic margin; local recurrence; mast cell tumour

Mesh:

Year:  2013        PMID: 23451809     DOI: 10.1111/vco.12021

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  16 in total

1.  The effect of prednisone on histologic and gross characteristics in canine mast cell tumors.

Authors:  Ken J Linde; Stephen L Stockdale; Michael B Mison; James A Perry
Journal:  Can Vet J       Date:  2021-01       Impact factor: 1.008

2.  Combination vinblastine and palladia for high-grade and metastatic mast cell tumors in dogs.

Authors:  Johanna E Todd; Sandra M Nguyen; Joanna White; Veronika Langova; Penelope M Thomas; Sophia Tzannes
Journal:  Can Vet J       Date:  2021-12       Impact factor: 1.008

3.  Uterine mast cell tumor: a clinical and cytohistopathological study.

Authors:  Ali Mohammad Bahrami; Fariba Khaki; Shahram Zehtabian; Javad Cheraghi; Mehdi Rashnavadi; Mohammad Reza Hafezi Ahmadi; Mostafa Naderafif; Soheil Javaherypour; Siamak Mohsenzadeh; Ehsan Hosseini; Hamed Masoudi; Mehdi Pourzaer
Journal:  J Ovarian Res       Date:  2014-11-07       Impact factor: 4.234

4.  Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study).

Authors:  Galina V Ilyinskaya; Elena V Mukhina; Alesya V Soboleva; Olga V Matveeva; Peter M Chumakov
Journal:  Front Vet Sci       Date:  2018-06-04

5.  Evaluation of information presented within mast cell tumour histopathology reports in the United States: 2012-2015.

Authors:  Jennifer K Reagan; Laura E Selmic; Caroline Fallon; Elizabeth A Driskell; Laura D Garrett
Journal:  Vet Med Sci       Date:  2018-06-07

6.  Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs.

Authors:  Jaime A Olsen; Maurine Thomson; Kathleen O'Connell; Ken Wyatt
Journal:  Vet Med Sci       Date:  2018-05-24

Review 7.  Oncolytic Viruses for Canine Cancer Treatment.

Authors:  Diana Sánchez; Gabriela Cesarman-Maus; Alfredo Amador-Molina; Marcela Lizano
Journal:  Cancers (Basel)       Date:  2018-10-27       Impact factor: 6.639

8.  A systematic review of surgical margins utilized for removal of cutaneous mast cell tumors in dogs.

Authors:  Laura E Selmic; Audrey Ruple
Journal:  BMC Vet Res       Date:  2020-01-06       Impact factor: 2.741

9.  Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate.

Authors:  Pamela D Jones; Justine E Campbell; Graham Brown; Chad M Johannes; Paul Reddell
Journal:  J Vet Intern Med       Date:  2020-12-22       Impact factor: 3.175

10.  Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46).

Authors:  Thomas R De Ridder; Justine E Campbell; Cheryl Burke-Schwarz; David Clegg; Emily L Elliot; Samuel Geller; Wendy Kozak; Stephen T Pittenger; Jennifer B Pruitt; Jocelyn Riehl; Julie White; Melissa L Wiest; Chad M Johannes; John Morton; Pamela D Jones; Peter F Schmidt; Victoria Gordon; Paul Reddell
Journal:  J Vet Intern Med       Date:  2020-06-16       Impact factor: 3.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.